Physician profile
Shefa Rahman
NPI 1124461942
$3,664.24
in general payments reported to CMS, 2019-2025
15 companies · $550 in 2025
The $550 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $130 · 2021: $149 · 2022: $187 · 2023: $1,915 · 2024: $453 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,044 · Travel and Lodging: $874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,043.56 |
| Travel and Lodging | $874.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $1,386.52 | 2023 | Neurostar Tms Therapy System |
| Alkermes, INC. | $545.94 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Vanda Pharmaceuticals INC. | $462.25 | 2019-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $329.50 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Otsuka America Pharmaceutical, INC. | $293.31 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Indivior INC. | $211.11 | 2019-2024 | Perseris |
| Abbvie INC. | $124.27 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $87.72 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $72.05 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $55.74 | 2025 | Uzedy |
| Neurocrine Biosciences, INC. | $29.92 | 2019-2023 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $22.89 | 2023 | Quviviq |
| Lundbeck LLC | $18.32 | 2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.29 | 2022 | |
| Allergan, INC. | $11.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shefa Rahman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.